GRM5 and psychotic disorder: With several neurotransmitters and neuromodulators involved in the presentation of symptoms, it is valuable to continue targeting mGlu5 and A(2A) receptors as we further elucidate aspects of psychosis that can contribute to improved patient outcomes.